Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/3/2019
SIETES contiene 92692 citas

 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]
2.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
3. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
4.Enlace a cita original
Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf 2016;25:713-8. [Ref.ID 100396]
5. Cita con resumen
Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]
6. Cita con resumen
Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-3. [Ref.ID 98401]
7.Tiene citas relacionadas Cita con resumen
Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349:g4517. [Ref.ID 98146]
9.Tiene citas relacionadas Cita con resumen
Moore TJ. New drug: caution indicated: Comment on "New drugs and safety". Arch Intern Med 2012;1721:1681-2. [Ref.ID 94147]
10. Cita con resumen
Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLOS ONE 2011;6:e27016. [Ref.ID 91685]
11. Cita con resumen
Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf 2009;32:335-43. [Ref.ID 85765]
12.Enlace a cita original Cita con resumen
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine 2008;5:e45. [Ref.ID 82220]
13. Cita con resumen
Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]
Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med 2004;164:1192-6. [Ref.ID 70423]
15.Tiene citas relacionadas Cita con resumen
Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N, for the DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med 2001;135:1019-28. [Ref.ID 60606]
Moore TJ, Psaty B M, Furberg CD. Time to act on drug safety. JAMA 1998;279:1571-3. [Ref.ID 38412]
17. Cita con resumen
Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin P-H, Karanja N, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24. [Ref.ID 31672]
Seleccionar todas
 1 a 17 de 17